Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 4/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | TLR2 | O60603 | 2/20 | 0.35 |
| ▸ | MMP2 | P08253 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25827441 | 0.82 | LMNA (0.42) | LMNAALDH1A1HTTMAPTEPHX2 | |
| SCHEMBL7078022 | 0.80 | — | — | |
| SCHEMBL12322931 | 0.80 | LMNA (0.43) | LMNAALDH1A1HTTMAPTEPHX2 | |
| Hydrochloric Acid SCHEMBL593628 | 0.78 | LMNA (0.52) | LMNAALDH1A1HTTMAPTTSHR | |
| SCHEMBL31326706 | 0.78 | LMNA (0.69) | LMNAMAPTEPHX2 | |
| SCHEMBL10820629 | 0.78 | LMNA (0.48) | LMNAALDH1A1HTTMAPTEPHX2 | |
| SCHEMBL5811678 | 0.77 | LMNA (0.47) | LMNAALDH1A1HTTMAPTEPHX2 | |
| SCHEMBL13239300 | 0.77 | LMNA (0.41) | LMNAALDH1A1HTTMAPTEPHX2 | |
| SCHEMBL4111843 | 0.76 | LMNA (0.43) | LMNAALDH1A1HTTMAPTEPHX2 | |
| SCHEMBL11220822 | 0.76 | LMNA (0.47) | LMNAALDH1A1HTTMAPTEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240216513-A1 | FATTY ACID-BIFUNCTIONAL DEGRADER CONJUGATES AND THEIR METHODS OF USE | NOVARTIS AG (CH) | 2024-07-04 | — | — | US | disclosed |
| WO-2023125792-A1 | MULTI-SUBSTITUTED URACIL DERIVATIVE AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 杭州奥默医药股份有限公司 | 2023-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240216513-A1 | FATTY ACID-BIFUNCTIONAL DEGRADER CONJUGATES AND THEIR METHODS OF USE | FASN, FABP1, SCD | LMNA 2491/4885ALDH1A1 634/4885HTT 1327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.